IOBT - IO Biotech Appoints Faiçal Miyara Ph.D. as Chief Business Officer | Benzinga
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately.
"We are very excited to welcome Faiçal to IO Biotech," said Dr. Zocca. "His deep experience in business development with proven ability to execute strategic transactions will be invaluable as we look at opportunities to advance our wholly owned proprietary T-Win platform. The coming months will be a critical period for the development of our company with the outcome of the pivotal Phase 3 interim analysis of our lead therapeutic cancer vaccine, IO102-IO103, expected in the third quarter of this year, as well as the readout of the primary endpoint of progression free survival estimated to follow in the second half of 2025."
Dr. Miyara added, "I am thrilled to join the IO Biotech team at this important time in the company's development. I believe the novel dual-mechanism approach of the vaccines being developed is very promising and has the potential to significantly improve the current treatment paradigm for people living with cancer. I look forward to developing new partnerships to further progress the company's growing portfolio."
Dr. Miyara is a seasoned executive with nearly two decades of experience in the pharmaceutical and biotechnology industry with a track record of successful deals and partnerships across several key therapeutic areas. Most recently, he served as Vice President, Head of Business Development Oncology, then Head of External Innovation Oncology, Lead on Venture Capital Activities at Ipsen Biosciences. Prior to this ...